Découvrez le nouveau Chem-Impex : là où l'innovation commence par une liaison.

Catalog Number:
38257
CAS Number:
49763-96-4
Stiripentol
Purity:
98,5 - 102,0 % (dosage, sur une base sèche)
Synonym(s):
4,4-Diméthyl-1-(3,4-méthylènedioxyphényl)-1-pentène-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-diméthyl-1-pentène-3-ol
Documents
$251.68 /1G
Taille
Request Bulk Quote
Informations sur le produit

Stiripentol is a unique compound recognized for its significant role in the treatment of epilepsy, particularly in patients with Dravet syndrome. This compound acts as a potent anticonvulsant, enhancing the efficacy of other antiepileptic medications. Its mechanism of action involves modulation of GABAergic and glutamatergic neurotransmission, making it a valuable addition to therapeutic regimens aimed at controlling seizures. Stiripentol is particularly beneficial in combination therapies, where it has been shown to reduce seizure frequency and improve overall patient outcomes.

In addition to its therapeutic applications, Stiripentol is also of interest in research settings, where it is being studied for its potential neuroprotective effects and its ability to influence metabolic pathways. This compound's unique chemical structure allows for targeted interactions within the central nervous system, making it a subject of ongoing investigation in the field of neuropharmacology. Researchers and healthcare professionals can leverage Stiripentol's properties to explore new treatment avenues and enhance existing protocols for managing refractory epilepsy.

Numéro CAS 
49763-96-4
Formule moléculaire
C14H18O3
Poids moléculaire 
234.3
Point de fusion 
73 - 78 °C
Informations générales
Numéro CAS 
49763-96-4
Formule moléculaire
C14H18O3
Poids moléculaire 
234.3
Point de fusion 
73 - 78 °C
Propriétés
Informations complémentaires sur la propriété à venir prochainement !
-
Sécurité et réglementation
Matières dangereuses
-
Antibiotique
-
Réglementé par la DEA
Non
Avertissements 
-
Applications

Stiripentol is widely utilized in research focused on:

  • Epilepsy Treatment: Primarily used as an adjunctive therapy for patients with Dravet syndrome, a severe form of epilepsy, helping to reduce the frequency of seizures.
  • Pharmaceutical Development: Employed in the formulation of new medications, particularly in combination therapies, to enhance efficacy and patient outcomes in epilepsy management.
  • Neuroscience Research: Investigated for its neuroprotective properties, contributing to studies on brain health and potential applications in other neurological disorders.
  • Drug Interaction Studies: Used in research to understand how it interacts with other antiepileptic drugs, aiding in the development of safer and more effective treatment regimens.
  • Clinical Trials: Involved in various clinical studies to assess its long-term effects and benefits, providing valuable data for healthcare professionals and researchers.

Citations